UBS AM
SGTX

UBS AM’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

UBS AM’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,490
Closed -$2.76M – 2790
2021
Q1 		$2.76M Sell
9,490
-125
-1% -$49.7K ﹤0.01% 1623
2020
Q4 		$6M Buy
+9,615
New +$4.36M ﹤0.01% 1219

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM's SGTX Position: Q2 2021 in Review

UBS AM sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2021, closing a stake of 9,490 shares — an estimated $2.76M sold.

UBS AM first reported a position in SGTX in Q4 2020 and held it in 2 quarters. The position peaked at $6M in Q4 2020. 52 funds tracked by Wall St. Rank hold SGTX as of Q2 2021.

  • UBS AM reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • UBS AM sold 9,490 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $2.76M.
  • UBS AM first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • UBS AM's Sigilon Therapeutics, Inc. Common Stock position peaked at $6M in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.